NYSEAMERICAN:TRXC - TransEnterix Stock Price, Forecast & News

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

TransEnterix, Inc. (NYSEAMERICAN:TRXC) released its quarterly earnings data on Tuesday, November, 12th. The medical instruments supplier reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.02. The medical instruments supplier earned $2.02 million during the quarter, compared to the consensus estimate of $4.68 million. View TransEnterix's Earnings History.

TransEnterix is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for TransEnterix.

3 Wall Street analysts have issued 1 year price objectives for TransEnterix's stock. Their forecasts range from $1.00 to $3.00. On average, they expect TransEnterix's stock price to reach $1.87 in the next twelve months. This suggests a possible upside of 34.3% from the stock's current price. View Analyst Price Targets for TransEnterix.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for TransEnterix.

Press coverage about TRXC stock has been trending negative this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. TransEnterix earned a coverage optimism score of -2.2 on InfoTrie's scale. They also assigned media stories about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for TransEnterix.

TransEnterix saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,380,000 shares, an increase of 14.4% from the December 15th total of 2,080,000 shares. Based on an average trading volume of 424,700 shares, the short-interest ratio is presently 5.6 days. Approximately 15.4% of the shares of the stock are sold short. View TransEnterix's Current Options Chain.

Some companies that are related to TransEnterix include SDI (SDI), Milestone Scientific (MLSS), IsoRay (ISR), Retractable Technologies (RVP), Impression Healthcare (IHL), TSO3 (TOS), Daxor (DXR), Daxor (DXR), G Medical (GMV), Omega Diagnostics Group (ODX), Akers Biosciences (AKR), Vigil Health Solutions (VGL), Relevium Technologies (RLV), Ambu A/S (AMBBY) and ANSELL LTD/S (ANSLY).

Based on aggregate information from My MarketBeat watchlists, some companies that other TransEnterix investors own include Oramed Pharmaceuticals (ORMP), Compugen (CGEN), Editas Medicine (EDIT), Ekso Bionics (EKSO), XOMA (XOMA), Actinium Pharmaceuticals (ATNM), Geron (GERN), NVIDIA (NVDA), Opko Health (OPK) and Advanced Micro Devices (AMD).

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TRXC stock can currently be purchased for approximately $1.39.

TransEnterix has a market capitalization of $27.33 million. View Additional Information About TransEnterix.

The official website for TransEnterix is http://www.transenterix.com/.

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.